Kynam Capital Management, LP Olema Pharmaceuticals, Inc. Transaction History

Kynam Capital Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$8.19 - $12.98 $8.76 Million - $13.9 Million	-1,069,156 Reduced 81.97%	235,176 $2.9 Million
Q2 2023 Aug 14, 2023	SELL	$3.22 - $9.65 $2.28 Million - $6.83 Million	-707,521 Reduced 35.17%	1,304,332 $11.8 Million
Q1 2023 May 15, 2023	SELL	$2.55 - $4.97 $34,121 - $66,503	-13,381 Reduced 0.66%	2,011,853 $6.98 Million
Q4 2022 Feb 14, 2023	BUY	$2.27 - $3.76 $1.42 Million - $2.35 Million	625,601 Added 44.7%	2,025,234 $4.96 Million
Q3 2022 Nov 14, 2022	BUY	$2.72 - $5.88 $3.13 Million - $6.76 Million	1,150,404 Added 461.59%	1,399,633 $3.86 Million
Q2 2022 Aug 15, 2022	SELL	$2.04 - $4.61 $64,459 - $145,666	-31,598 Reduced 11.25%	249,229 $1.01 Million
Q1 2022 May 13, 2022	SELL	$3.89 - $9.43 $50,461 - $122,325	-12,972 Reduced 4.42%	280,827 $1.2 Million
Q4 2021 Feb 14, 2022	BUY	$8.75 - $30.71 $2.57 Million - $9.02 Million	293,799 New	293,799 $2.75 Million

139

58.8M

141K

23.1K

Ticker OLMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,419,600
Market Cap $247M
Description
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...

Get notified when there are updates to the investment portfolio of Kynam Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Kynam Capital Management, LP with notifications on news.